OBJECTIVE: To describe our experience with office removal of nonpalpable contraceptive implants at our referral center.
RESULTS: Of 61 referrals, 55 patients attended their scheduled appointments. Seven patients had palpable implants; six elected removal. The other 48 patients had ultrasound localization, which identified 47 (98%) of the implants; the remaining patient had successful localization with computed tomography imaging. Nonpalpable implants were suprafascial (n522), subfascial (n525) and intrafascial (n51); four of these patients opted to delay removal. Of 50 attempted office removals, all palpable (n56), all nonpalpable suprafascial (n521 [100%, 95% CI 83-100%]), and 19 out of 23 (83%, 95% CI 67-98%) subfascial implants were successful. Three of the four patients with failed subfascial implant office removal had successful operating room removal with a collaborative orthopedic surgeon; the other patient sought removal elsewhere. Transient postprocedure neuropathic complaints were noted in 7 out of 23 (30%, 95% CI 12-49%) subfascial and 1 out of 21 (5%, 95% CI 0-13%) suprafascial removals (P5.048). Nonpalpable implants were more likely to be subfascial in nonobese patients (24/34, 71%) as compared with obese (1/13, 8%) patients (P,.001). Seven (28%) of the 25 subfascially located implants had been inserted during a removal-reinsertion procedure through the same incision.
CONCLUSION: Most nonpalpable contraceptive implants can be removed in the office by an experienced subspecialty health care provider after ultrasound localization. Some patients may experience transient postprocedure neuropathic pain. Nonpalpable implants in thinner women are more likely to be in a subfascial location.
I nstructions for contraceptive subdermal implant insertion have changed over the past decade, primarily inspired by complications related to deep insertions, including intravascular placement and pulmonary artery migration. [1] [2] [3] [4] The most recent recommendation for optimal placement is between the dermis and the subcutaneous tissue in the area of the arm over the triceps muscle, with the intent to minimize neurovascular injury should deep insertion inadvertently occur.
Overall, major complications with insertion and removal are exceedingly rare. 5 Deep implant insertions are estimated to occur approximately one out of every 1,000 insertions, 5,6 similar to the perforation rate of intrauterine devices. 7, 8 Severe complications associated with deep placement, such as intravascular placement with pulmonary embolization, are estimated to occur in just more than one patient per 1 million implants sold. 4 Referral to a specialty center with physicians who have expertise localizing and removing nonpalpable implants is essential. 9 Health care providers have described various advanced techniques to localize and remove nonpalpable implants 6, [9] [10] [11] [12] [13] [14] [15] [16] ; however, the reports typically only include descriptions with a few patients and often involve costly resources such as interventional radiology, fluoroscopy, and removal in the operating room. 6 In the United Kingdom, the Faculty of Sexual and Reproductive Healthcare established a formal network of expert removal centers more than a decade ago 17 ; however, only in the past few years has a similar specialty removal network been developed in the United States. This network is not outwardly advertised by the etonogestrel implant manufacturer (Merck & Co), and a comprehensive description of the experience of any such specialty removal center has never been presented. This report aims to describe the experience of our fellowship-trained family planning specialty division as a regional referral center for nonpalpable implant removals. We aim to describe our referral population, clinical outcomes and what we have learned from caring for these patients. This information is important for all contraceptive providers to understand the complexity of such a referral program, as well as the advanced techniques and outcomes of nonpalpable implant removals.
METHODS
After obtaining institutional review board approval from the University of California, Davis, we performed a retrospective cohort study by reviewing our implant referral clinical log to identify patients referred to our family planning specialty clinic in the Department of Obstetrics and Gynecology for nonpalpable or complex implant removal between January 2015 and December 2018. The first three patients in this series have been previously reported. 6 All patients were seen by a family planning fellow supervised by a family planning attending with fellowship training in nonpalpable implant removals. Patients referred to our program have an initial contact with our family planning coordinator, who organizes receipt of outside medical records and obtains insurance authorization, often for out-of-network referral and radiologic examinations. If insurance approval is obtained, the patient has a concomitant appointment scheduled in our family planning clinic and radiology for an upper extremity ultrasound examination. For a typical appointment, the patient first meets with the specialists who assess reasons for removal, ongoing symptoms or problems related to any prior removal attempts, and if the implant is palpable. Patients with nonpalpable, partially palpable or questionably palpable implants have ultrasound localization in the radiology suite using a 15-18-MHz linear array transducer to evaluate implant relationship to fascia and neurovascular structures; during localization, the family planning specialists map the implant location on the skin with a surgical marker ( Fig. 1 ). Implant removal then occurs in the office using a technique we have previously described with a modified vasectomy clamp under local anesthesia through an incision that is typically about 5 mm or less. 6 While removing the implant, sharp instruments are used only for skin and fascial incisions. Dissection is performed with blunt forceps or a modified vasectomy clamp. Patients with unsuccessful office removal attempts are scheduled for an operating room removal procedure with a collaborative orthopedic surgeon. One of the family planning specialists assists for implant identification, because the implant can appear similar to neurovascular structures in the upper arm.
We reviewed the electronic medical records of all patients in our database during the study period to abstract demographic information, medical histories, implant specific data and clinical outcomes. Our primary goal was to assess successful in-office removal of the implant. We also evaluated the proportion of patients referred compared with those seen in the clinic as well as evaluation of the effect of body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and reinsertion of index implant through removal incision on subfascial location, and clinical outcomes including postprocedure complications. We arranged follow-up by phone or in the office for women that had postprocedure complaints until resolution or a diagnosis was made. We used Fisher exact tests for dichotomous variables and t test for continuous variables. We assessed normality of age, BMI and distance traveled by histograms and Q-Q plots; all data were normally distributed. All data were analyzed with SAS 9.4.
RESULTS
Of 61 referrals, 55 (90%) patients presented for their scheduled appointment; the characteristics are presented in Table 1 . The median distance traveled was 20.8 miles (range 1.5-179 miles). The number of referrals seen in the clinic annually increased from five in 2015 to 26 in 2018. Primary reasons for referral included failed attempt at removal by the referring health care provider (n529) for both palpable (n56) and nonpalpable (n523) implants, or concern for deeply placed, abnormally located or nonpalpable implant without a removal attempt (n526). The number of patients experiencing at least one removal attempt before referral remained constant at about 50% over the 4-year time period (2/5, 4/8, 10/16, and 13/26 in 2015, 2016, 2017, and 2018, respectively). Figure 2 outlines the outcomes of our assessments and removal attempts. Overall, three patients with either a palpable, intrafascial or suprafascial implant opted to continue use after counseling, and two with subfascial implants did not have removal attempts by our team after initial evaluation. Of the 50 attempted office Table 2 compares the effect of BMI as a predictor of subfascial location. Nonpalpable implants were more likely to be subfascial in nonobese (24/34, 71%) patients as compared with obese (1/13, 8%) patients (P,.001). Fifteen patients referred to our Fig. 2 . Referral flowsheet of our clinical assessments and outcomes. OR, operating room. *Three patients opted to continue use of implant: one palpable implant had 1 additional year of extended use; patient with intrafascial implant continued use owing to time constraints after evaluation and counseling, aware she must return to specialty center at time of desired removal; patient with suprafascial implant referred with acute cellulitis immediately after insertion, at consultation, cellulitis was resolved and implant partially palpable (ultrasound localization confirmed implant location). † Two implants initially not localized by ultrasound scan, identified using X-ray, repeat ultrasound scan located implants with minimal shadowing. ‡ Subfascial implant identified with X-ray then localized with computed tomography; patient ultimately lost to follow-up owing to insurance authorization issues. § One subfascial and one suprafascial implant required removal in ultrasound suite for direct ultrasound guidance; all others were successfully removed with skin mapping technique in office.
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specialty referral center had used a contraceptive implant in the past, eight of whom were known to have reinsertion of the index implant through the removal incision. One of these implants was palpable on our initial examination, and the other seven (88%) were nonpalpable and subfascial. Six (86%) of the seven nonpalpable subfascial implants were in patients with BMIs of less than 30.
DISCUSSION
At our family planning specialty referral center, 92% of nonpalpable or complicated implants were successfully removed in the office. Importantly, we averted a large incision in the operating room in 83% of those with subfascial implants. However, nearly one-third of these patients reported transient postprocedure neuropathic complaints, albeit limited in duration; this information should be incorporated into preprocedure counseling. Our findings suggest that a nonpalpable implant in nonobese patients is highly likely to be subfascial. In these cases, health care providers without advanced removal training should probably avoid attempting removal and refer to a specialty center. Although our data also suggest a potential association between reinsertion through a removal incision and subfascial placement, the analysis is limited owing to the small numbers. To test this hypothesis the appropriate comparison group would have to be a group of women who had a second implant placed through a separate incision. However, the link is plausible and until additional data are available, health care providers should maintain caution when performing a removal and reinsertion procedure.
More than 50% of our patients had prior removal attempts before referral, with 16% having had two or more failed attempts. We expected this proportion to decrease over time as the community grew more aware of our specialty center; however, the rates remained stable. Clearly, more targeted education for clinic staff, health care providers, and patients is warranted. The U.S. Food and Drug Administrationmandated implant insertion and removal training would provide an excellent opportunity for education about early referral for nonpalpable or deep implants, and we encourage that specific information about the U.S. specialty removal network be added to the program.
We use ultrasonography for primary implant localization, which provides the ability to mark the position of the implant and identify nearby vascular structures. Transducers with a frequency of 5 or 7.5 MHz, which are commonly available in an obstetrician-gynecologist's office, can be used to identify correctly placed implants. 18 Frequencies of 10 MHz or greater are more useful with nonpalpable implants, because these frequencies can identify an implant in both suprafascial and subfascial locations. 19 We have found that newer 15-and 18-MHz transducers, which are developed primarily for extremity visualization, are an important tool, especially for subfascial implants.
Our outcomes confirm the utility of highfrequency ultrasound localization of nonpalpable implants and demonstrate the importance of a specialty referral center for removal. Our experience with subfascial implant removal in the office is unique. We were obligated to develop this process owing to scheduling limitations for implant removals under direct ultrasound guidance in the radiology suite. Because deep implant placement is rare, this report represents a relatively large series. Still, the numbers are too small to support any predictive multivariable analyses.
Our outcomes provide essential information for all clinicians who see patients using contraceptive implants to ensure appropriate counseling and decision-making when removal is desired and the implant is not easily palpable. Health care providers who cannot easily palpate the implant at the time of 
